Gene
CDH1
CDH1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (172), Actionable biomarkers (1), Trial mentions (57), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CDH1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 dated before 1990 and 20 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 8 of 8,738 | 0.09% | not measured | |
| 2025 | 7 of 8,875 | 0.08% | not measured | |
| 2024 | 9 of 8,597 | 0.10% | not measured | |
| 2023 | 1 of 8,275 | 0.01% | 52 of 11,460 | 0.45% |
| 2022 | 4 of 8,285 | 0.05% | 61 of 13,598 | 0.45% |
| 2021 | 1 of 8,692 | 0.01% | 106 of 15,045 | 0.70% |
| 2020 | 1 of 7,640 | 0.01% | 87 of 14,459 | 0.60% |
| 2019 | 4 of 7,300 | 0.05% | 95 of 12,159 | 0.78% |
| 2018 | 1 of 6,927 | 0.01% | 73 of 11,854 | 0.62% |
| 2017 | 2 of 6,558 | 0.03% | 81 of 11,595 | 0.70% |
Showing 10 of 37 years.
Assay-provider ledger (172)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Agilent | Reagent supplier | Analytical validation | 2 | December 01, 2025 |
| BIOCARE MEDICAL LLC | Reagent supplier | Clinical validationAnalytical validation | 2 | December 01, 2025 |
| Cytocell | Diagnostic provider | Analytical validation | 1 | December 01, 2025 |
| Epredia | Unclassified | Analytical validation | 1 | December 01, 2025 |
| Histopathology Ltd | Unclassified | Analytical validation | 1 | December 01, 2025 |
Showing 5 of 172 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CDH1 oncogenic mutation | Bicalutamide | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (57)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT00908739 | Trial biospecimen (AACT) |
| NCT07141758 | Trial biospecimen (AACT) |
| NCT06163365 | Trial biospecimen (AACT) |
| NCT05058170 | Trial biospecimen (AACT) |
| NCT06712095 | Trial eligibility (AACT) |
Showing 5 of 57 trial mentions.
Target-disease associations (988)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| AIDS dementia | infectious disease | Literature (Europe PMC) |
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Adenoid Cystic Breast Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Agouti-related protein measurement | measurement | GWAS credible sets |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
Showing 5 of 988 associations.
Vendor sourcing (222)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The CDH1 c.1136C>T; p.Thr379Met variant (rs587782856) is reported in the literature in individuals affected with cancer (Garcia-Pelaez 2023, Guindalini 2022)... | View ClinVar record SCV004563165.2 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The p.Y755C variant (also known as c.2264A>G), located in coding exon 14 of the CDH1 gene, results from an A to G substitution at nucleotide position 2264. T... | View ClinVar record SCV000172725.10 |
| AnHeart Therapeutics Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Age ≥18 years 2. History of histologically or cytologically confirmed diagnosis invasive lobular carcinoma and current diagnosis of metastatic breast c... | View trial NCT06214793 |
| AnHeart Therapeutics Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | CDH1 | View trial NCT06214793 |
| Assistance Publique – Hôpitaux de Paris | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : Case: * Patient ≥ 18 years old * CDH1 or CTNNA1 germline pathogenic variant. * No history of diffuse gastric cancer. * French social security. * Ability ... | View trial NCT04253106 |
Showing 5 of 222 sourcing records.
Trial-cited literature (1,082)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Reciprocal regulation of hMENA and TGF-β signaling in cancer-associated fibroblasts promotes EMT, immunosuppression, poor prognosis, and ICT resistance in NSCLC. | Journal for immunotherapy of cancer | 2026 | 1 |
| Multiomic profiling of ER-positive HER2-negative breast cancer reveals markers associated with metastatic spread. | Breast cancer research : BCR | 2026 | 0 |
| The Istanbul consensus update: a revised ESHRE/ALPHA consensus on oocyte and embryo static and dynamic morphological assessment†,‡. | Human reproduction (Oxford, England) | 2025 | 57 |
| Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group. | Cancer treatment reviews | 2025 | 11 |
| Fecal microbiota transplantation for refractory chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation: a pilot open-label, non-placebo-controlled study. | BMC medicine | 2025 | 7 |
Showing 5 of 1,082 papers.
Protein variant mentions (323)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A226V | 2 | 2015 to 2018 | PMID 30311375, PMID 25741868 |
| p.A289T | 2 | 2015 to 2016 | PMID 26467025, PMID 25741868 |
| p.A289V | 2 | 2015 to 2018 | PMID 30311375, PMID 25741868 |
| p.A301T | 2 | 2015 to 2018 | PMID 30311375, PMID 25741868 |
| p.A401T | 1 | 2015 | PMID 25741868 |
Showing 5 of 323 variants.
Human sample screening reference (1)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.Q641* | TCGA-BRCA | Cystic, Mucinous and Serous Neoplasms; Adenomas and Adenocarcinomas; Fibroepithelial Neoplasms; Basal Cell Neoplasms; Ductal and Lobular Neoplasms; Epithelial Neoplasms, NOS; Squamous Cell Neoplasms; Complex Epithelial Neoplasms; Adnexal and Skin Appendage Neoplasms; Breast | 1 | 1,098 | 0.09% | 0.02% to 0.51% |
Literature-extracted relations (238)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Crizotinib | Chemical | negative_correlate |
E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. | 2018 |
| Probucol | Chemical | positive_correlate |
Protective effects of probucol on Ox-LDL-induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells via LOX‑1/ROS/MAPK signaling. | 2018 |
| Iodine | Chemical | negative_correlate |
Molecular iodine impairs chemoresistance mechanisms, enhances doxorubicin retention and induces downregulation of the CD44+/CD24+ and E-cadherin+/vimentin+ subpopulations in MCF-7 cells resistant to low doses of doxorubicin. | 2017 |
| Decitabine | Chemical | positive_correlate |
Effects of Decitabine on Invasion and Exosomal Expression of miR-200c and miR-141 in Oxaliplatin-Resistant Colorectal Cancer Cells. | 2015 |
| Crizotinib | Chemical | associate |
Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin-Deficient Cells. | 2015 |
Showing 5 of 238 relation assertions.
Organizations publishing (684)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 37 | 1991 to 2025 |
| Harvard Medical School | Academic | 32 | 2004 to 2023 |
| Memorial Sloan Kettering Cancer Center | Hospital | 32 | 1998 to 2025 |
| The University of Texas System | Academic | 30 | 2002 to 2023 |
| Mass General Brigham | Hospital | 24 | 2011 to 2023 |
Showing 5 of 684 organizations.
Where CDH1 appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
857 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.